Sign in
Back
Comparison of the efficacy of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candida albicans infection in the neutropenic mouse
Journal article   Peer reviewed

Comparison of the efficacy of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candida albicans infection in the neutropenic mouse

R M Bannatyne, P C Cheng and I W Fong
Infection, Vol.20(3), pp.168-170
01/05/1992
DOI: https://doi.org/10.1007/BF01704614
PMID: 1644494

Abstract

Amphotericin B - pharmacokinetics Amphotericin B - pharmacology Amphotericin B - therapeutic use Animals Antifungal Agents - pharmacokinetics Antifungal Agents - pharmacology Antifungal Agents - therapeutic use Candidiasis - drug therapy Candidiasis - mortality Candidiasis - pathology Colony Count, Microbial Disease Models, Animal Drug Evaluation, Preclinical Echinocandins Female Fluconazole - pharmacokinetics Fluconazole - pharmacology Fluconazole - therapeutic use Fungemia - drug therapy Fungemia - mortality Fungemia - pathology Kidney - microbiology Liver - microbiology Lung - microbiology Mice Neutropenia - complications Peptides - pharmacokinetics Peptides - pharmacology Peptides - therapeutic use Peptides, Cyclic Spleen - microbiology Survival Rate
The relative efficacies of cilofungin, amphotericin B and fluconazole were compared in the treatment of systemic Candida albicans infection in neutropenic mice. Thirty-one day survival rates were lowest for cilofungin (14.6%), intermediate for amphotericin B (37.6%) and highest for fluconazole (50.5%). Residual tissue infection in surviving animals was observed with all agents, but was heaviest with fluconazole, especially in the kidneys.

Metrics

1 Record Views

Details